SPA17 and ovarian clear cell cancer: Additional studies have shown that SP17 is associated with chemotherapy resistance of ovarian clear cell carcinoma, and the inhibition of SP17 can enhance the sensitivity of clear cell carcinoma ES‐2 to paclitaxel.77, 94